LONDON, Dec. 1, 2018 /PRNewswire/ -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, today announced that the first patient has been dosed in its Phase 1/2 LibrA T1...
from PR Newswire: https://ift.tt/2QuhPtr
No comments:
Post a Comment